A Phase 2 interventional study of Ferric Carboxymaltose (FCM) and Iron Sucrose / Iron Dextran in Iron Deficiency Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-02-08.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 38th largest by enrollment, is one of 6 that started in 2009, is one of 8 in phase 2, and was the 13th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Hawler Medical University
Ages 18–45 · Women only
Zhaojian Niu,MD
Ages 18–75
Children's Hospital of Orange County
Ages 1–18
Liverpool Hope University
Ages 60–85
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 24
First in 2006; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is below the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 57 interventional studies. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2009, is one of 4 in phase 2, and was the 5th registered.
Daiichi Sankyo’s Anemia, Iron-Deficiency studies by the year they started, since 2009.
2 of the studies testing ferric carboxymaltose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
| NCT07772453Zhaojian Niu,MDFerric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, from their registry updates:
Among Daiichi Sankyo’s 13 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare safety and the oxidative stress potential of two doses of an investigational IV iron, ferric carboxymaltose (FCM), compared to an equal single dose of IV iron sucrose or IV iron dextran in the treatment of Iron Deficiency Anemia (IDA) in female subjects.
This was a Phase 2a, open-label, multicenter, randomized study that compared the safety and oxidative stress potential of FCM vs. IV iron sucrose or IV iron dextran in female subjects with IDA. Subjects with a diagnosis of IDA who required iron supplementation met all inclusion and no exclusion criteria, and had given informed consent were randomized. The duration of the study for each subject was a maximum of 6 weeks.
Eligible subjects were randomized in a 1:1 ratio to FCM (Group A) or IV iron sucrose or IV iron dextran (Group B).
Group A subjects received a single undiluted dose of iron as FCM by a slow IV injection on Day 0. Cohort I received 500 mg and Cohort II received 750 mg. Group B subjects received a single dose of iron as IV iron sucrose or as IC iron dextran on Day 0. Cohort I receive 500 mg iron sucrose and Cohort II received 750 mg iron dextran. Iron dextran administration was preceded by a 25 mg test dose 1 hour prior to infusion.
All subjects had laboratory assessments at Baseline, 2 hours post-infusion, 24 hours post-infusion, Day 7 (drawn at the same time of day [within 4 hours] as the 24-hour visit), and Day 30 (drawn at the same time of day [within 4 hours] as the the 24-hour visit). On Days 7 and 30, the safety evalutation for all subjects included treatment-emergent adverse event reporting, concomitant medication review, physical examination including vital signs, and laboratory assessments. Any subject who withdrew from the study received a follow-up phone call 30 days after they received study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous iron
Drug: Ferric Carboxymaltose (FCM)
Intravenous iron
Drug: Iron Sucrose / Iron Dextran
One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
Also known as: Injectafer
Drug pages: Iron sucrose · Iron-Dextran Complex
One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
Also known as: Venofer, Dexferrum
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame: Change from Baseline to Day 30
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame: Change from baseline to 2 hours post end IV infusion
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame: Change from baseline to 24 hours post end IV infusion
Changes From Baseline in Markers of Oxidative Stress (Carbonyl and 8-isoprostane)
Time frame: Change from baseline to Day 7 post end IV infusion
Hospitals and Medical Clinics. December 6, 2010 through October 13, 2012.
| Milestone | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II |
|---|---|---|---|---|
| Started | 14 | 12 | 10 | 13 |
| Completed | 11 | 9 | 10 | 8 |
| Not completed | 3 | 3 | 0 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 |
| Withdrew: Selection criteria/compliance | 2 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 |
| mg | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II |
|---|---|---|---|---|
| Carbonyl | -11.90 ± 52.55 | -1.06 ± 38.722 | -12.37 ± 32.91 | -11.14 ± 48.57 |
| 8-isoprostane | 141.46 ± 892.16 | -369.50 ± 957.06 | 8.83 ± 81.20 | 32.28 ± 233.41 |
| mg | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II |
|---|---|---|---|---|
| Carbonyl | 2.07 ± 38.21 | 6.05 ± 24.69 | -8.66 ± 43.15 | -5.98 ± 23.71 |
| 8-isoprostane | 151.59 ± 833.75 | -420.02 ± 803.52 | -2.64 ± 30.44 | -5.92 ± 216.66 |
| mg | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II |
|---|---|---|---|---|
| Carbonyl | 8.63 ± 23.24 | -6.92 ± 21.49 | 8.94 ± 87.05 | -11.57 ± 40.30 |
| 8-isoprostane | 198.67 ± 864.29 | 119.26 ± 575.29 | -23.96 ± 60.01 | 38.02 ± 190.07 |
| mg | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II |
|---|---|---|---|---|
| Carbonyl | 11.69 ± 36.43 | -24.03 ± 65.55 | -18.20 ± 45.92 | -12.10 ± 54.85 |
| 8-isoprostane | 263.52 ± 896.57 | -417.89 ± 1030.83 | -29.35 ± 56.88 | -58.04 ± 159.58 |
Collected over 1 year and 10 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | — | 0/24 (0%) | 6/24 (25%) |
| Iron Sucrose or Iron Dextran | — | 2/25 (8%) | 10/25 (40%) |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose or Iron Dextran |
|---|---|---|
| Anaphylactic ReactionImmune system disorders | 0/24 | 2/25 |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose or Iron Dextran |
|---|---|---|
| HypersensitivityImmune system disorders | 2/24 | 2/25 |
| NauseaGastrointestinal disorders | 1/24 | 2/25 |
| Anaphylactic reactionImmune system disorders | 0/24 | 2/25 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 2/25 |
| Injection site bruisingGeneral disorders | 1/24 | 0/25 |
| HypophosphataemiaMetabolism and nutrition disorders | 1/24 | 0/25 |
| DizzinessNervous system disorders | 1/24 | 0/25 |
| VomitingGastrointestinal disorders | 0/24 | 1/25 |
| UrticariaSkin and subcutaneous tissue disorders | 0/24 | 1/25 |
| Age, Categorical(Participants) | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 12 | 10 | 13 | 49 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II | Total |
|---|---|---|---|---|---|
| Mean | 32.1 ± 7.66 | 29.6 ± 9.93 | 39.2 ± 7.97 | 39.2 ± 9.21 | 34.8 ± 9.48 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II | Total |
|---|---|---|---|---|---|
| Female | 14 | 12 | 10 | 13 | 49 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Ferric Carboxymaltose (FCM) Cohort I | Iron Sucrose Cohort I | Ferric Carboxymaltose (FCM) Cohort II | Iron Dextran Cohort II | Total |
|---|---|---|---|---|---|
| United States | 14 | 12 | 10 | 13 | 49 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2009 to primary completion in Mar 2013, 43 months.
Results were first posted in Feb 2018, 4 years 11 months after primary completion.
Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 43 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose